You will learn about:

• Tracing of dysregulated genes from post-mortem brain tissue to peripheral blood
• Determination of whether the above gene changes are disease specific
• Identification of genes that are related to aging rather than to CNS disease

Author: Jarlath ffrench-Mullen, PhD, Scientific Director, Gene Logic.

Download Case Study

Read Dr. Lupski’s interview…

Read Dr. Mattie’s interview…

http://etherpad.com/roT866i6Ls

Some ideas to use this dashboard:

* Introducing ourselves and share interesting information about our interests, findings, anything scientific really!
* Rate interesting genomics papers and share it with the users.
* Share/Review interesting papers and stuff you came across.
* Share information and get feedback on your work
* Share and rekindle classic science which has got lost over the years
* Start a debate on a burning topic of interest!
* We will also use this platform to hold interactive sessions with key thought leaders and use it for our regular -OMICs Saturday chats!
*You can also talk live to other genomics folks online.

Any more ideas Pioneers?

cheers,
Ashwin

New subgroups have been created within this group in our efforts at the Gateway to create an ecosystem for theme and purpose based networking amongst key stake holders and bodies in the -OMICS area for improved collaborations and knowledge dissemination. The sub-groups are meant to identify diverse representative groups who make up this gateway. This will hopefully contribute towards better communication between members of this group.

Please feel free to join clans (subgroups) which are most applicable to you.

Industry clans http://www.linkedin.com/groups?about=&gid=2402000
Industry participants in the Genomics Pioneers Gateway- Pharma, Biotech, Services companies, Agrotech and others

Society Clans http://www.linkedin.com/groups?gid=2402019
Representative members of leading Societies and Associations in the Genomic Pioneers Gateway

Academic Clans http://www.linkedin.com/groups?gid=2402231
Representative groups from leading research centers, universities and government organizations in the Genomic Pioneers Gateway

Media Clans http://www.linkedin.com/groups?gid=2402238
Global Media representatives at the Genomic Pioneers Gateway

thanks.

best regards,
Ashwin
—-
Group Coordinator
Genomic Pioneers Gateway
An Ocimum-Gene Logic Initiative
www.genomicpioneers.com
—-

Hencin: There’s certainly a shift away from the early target discovery days when people were searching madly for what kind of mechanistic things we could uncover with expression profiling. That’s still ongoing but it’s not the only thing. I think the shift has really been made to translational medicine. The question now is how can we take what we’ve learned in clinical and preclinical or tox studies and put it into the early phase clinical trials to develop markers to identify efficacy events or adverse events and more importantly to stratify the patients moving into trials to get a better population that’s going to save costs by not having as many non-responders. The biggest area of growth is in phase one and phase two clinical trials. I see the growth in areas where genomics can be applied in much larger trials and being able to have marker-based diagnostics that you will apply to your population to monitor it during the course the larger trials for both efficacy as well as adverse events. I think that the whole genomic ADME screening market is kind of a no brainer. You have to do this because there will be more of these markers that are almost mandated by FDA as well as pharmaceutical companies

Read the complete interview at the BioITworld website

The inaugural edition of our ‘On the Trail of Genomic Pioneers’ interview series features Prof. James R. Lupski, Department of Molecular and Human Genetics, Baylor College of Medicine. His research focuses on using human genetics, genomics, and molecular biological techniques to elucidate biological mechanisms for diseases. This interview gives fascinating insights into genomic disorders and discusses his research in this area.

Snippet from Prof. Lupski’s interview

“We do believe that CNV may be responsible for a lot more disease than currently believed or anticipated. The focus to date in approaches to human genetic traits has been, whether by virtue of the Mendelian model or a hypothesis generating search through genome-wide association studies (GWAS), the focus has been on base pair changes as being responsible for the variation leading to the genetic cause or susceptibility to disease traits. However, if we look just in the past year or two alone we have witnessed that when researchers open their minds to CNV as a mutational mechanism, and analyze their data with that thought in mind, one can find CNV being responsible for conditions such as autism and schizophrenia for which we previously have had a difficult time identifying specific genetic etiologies”

 Read more…

On the trail of Genomic Pioneers-James Lupski

Gaithersburg, Maryland, US, July 21, 2009: Genomic Pioneers Gateway has announced a call for partnership with societies, industry associations, regional biotech clusters and other likeminded forums for their upcoming programs. Genomic Pioneers Gateway is the thought leadership forum and ideation platform comprising thought leaders, key think tanks, companies, research centers and societies for envisioning and giving direction to the field of Genomics. This class is a ‘group of excellence’ which works together for creating affordable, novel and quality genomics driven solutions in key areas including improved healthcare & therapeutics, agriculture, food & nutraceuticals amongst other niche priority areas.

Read more…

The system for analyzing gene expression data obtained from a plurality of microarrays having mismatch (MM) probe pairs and perfect match (PM) probe pairs is automated. Image data for a plurality of scanned microarrays is stored in a database along with a set of microarray parameters which includes one or more image processing metrics for quality control of the microarray and a pass/fail status of the microarray as determined by these metrics. The user can search the database records according to one or more microarray parameters. The image processing metrics include algorithms for removing local background effects from the probe measurements by determining a model for estimated background using PM probe values.

A centralized application is provided for viewing, masking and pass/failing chips, and making use of the Image Processing (IP) metrics and limits. The application tracks the processes as a chip moves from registration and scan to publish and beyond. It permits users to view experiments, mask experiments if necessary, set pass/fail status and fail reason if fail, correct problems and view any of a number of chip parameters including IP (image processing) metrics and limits.

The Method and System for managing and querying gene expression data according to quality is covered by a patent in the name of Gene Logic. To know more about this patent, follow this link: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22ocimum+biosolutions%22&OS=”ocimum+biosolutions”&RS=”ocimum+biosolutions“

As always, Your Needs have Defined our Priorities!

Here is a cool browser tool bar. Works in Linux, Mac and Windows.

Enjoy.

cheers,

Ashwin

–

The Best of Our Site. Login and use your favourite sites like Twitter, Linkedin, Facebook et cetera in one window Get our freshest content delivered directly to your browser, no matter where you are on the Web.

Hand-picked Links Check out all of our favorite places on the Web.

Google-Powered Search Box Search the Web, our site, and other useful engines.

Alerts to Your Desktop Alerts to Your Desktop